One Case of Pustular Psoriasis Caused by Duvalumab Injection

doi:10.19803/j.1672-8629.20241018

Abstract

Abstract: Objective To analyze the clinical characteristics and mechanisms of pustular psoriasis caused by duvalumab injection so as to provide a reference for rational use of duvalumab injection. Methods One case of pustular psoriasis (PP) that was considered to have been caused by duvalumab was analyzed. Related literature was reviewed while the process of diagnosis and treatment, possible mechanisms, clinical manifestations and treatment regimens were summarized. Results Correlation analysis suggested that the immune-related adverse reactions of the skin in this patient were likely induced by durvalumab injection. After effective treatment with guselkumab and discontinuation of durvalumab injection, the patient’s symptoms of PP were relieved. Conclusion Durvalumab may induce PP via activation of the IL-36/IL-17 inflammatory axis. Clinicians should be alert to such immune-related adverse events (irAEs) to ensure early detection and quick interventions.

Key words: PD-1/PDL-1 Inhibitors, Duvalumab, Injection, Pustular Psoriasis, irAEs, Adverse Drug Reactions

CLC Number:

WEI Ying, LI Wenfeng, ZHANG Yufei, HOU Xin, YANG Yanwei, FAN Yongli. One Case of Pustular Psoriasis Caused by Duvalumab Injection[J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 1057-1060.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20241018

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I9/1057

References

[1] YANG LY, LIN S, XIE QB, et al.Current Status of Anti-Tumor PD-1 and PD-L1 Therapies and Mechanistic Exploration of Immune-related Adverse Reactions[J]. Chinese General Practice(中国全科医学), 2022, 25(11): 1393-1398, 1405.
[2] ELLIS SR, VIERRA AT, MILLSOP JW, et al.Dermatologic Toxicities to Immune Checkpoint Inhibitor Therapy: a Review of Histopathologic Features[J]. J Am Acad Dermatol, 2020, 83(4): 1130-1143.
[3] JIANG KFY, XU H, SONG LJ, et al.Literature Analysis of Adverse Reactions Induced by Durvalumab[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2022, 19(1): 1672-8157.
[4] SHOUKFEH R, YASSINE R, TURK D, et al.New-Onset Psoriasis Induced by Durvalumab[J]. Cureus, 2023, 15(11): e48453.
[5] GLEASON L, HUNTER E, COHEN A, et al.Atezolizumab-Induced Psoriasiform Drug Eruption Successfully Treated with Ixekizumab: a Case Report and Literature Review[J]. Dermatology Online Journal, 2023, 29(1): 9.
[6] CHEN M, MA HH, ZHAO RH, et al.A Case of Psoriasiform Drug Eruption Induced by PD-1 Inhibitor[J]. Chinese Journal of Leprosy and Skin Diseases(中国麻风皮肤病杂志), 2019, 35(8): 494-495.
[7] ANDRADE MM, TEJADA GL, PERUZZO J, et al.Pustular Psoriasis Triggered by Therapy with Atezolizumab and Bevacizumab[J]. Anais Brasileiros de Dermatologia, 2024, 99(1): 153-155.
[8] YANG SR, TAI RS, WANG G, et al.Problems Brought about by Immune Checkpoint Inhibitor Therapy-Immune-Related Adverse Events (irAEs)[J]. Chinese Journal of Immunology(中国免疫学杂志), 2022, 38(16): 2026-2030, 2036.
[9] BROWN AM, MASTERSON W, LO J, et al.Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: a Review[J]. Dermatitis, 2023, 34(3): 201-208.
[10] RIVERA-DÍAZ R, DAUDÉN E, CARRASCOSA JM, et al. Generalized Pustular Psoriasis: a Review on Clinical Characteristics, Diagnosis, and Treatment[J]. Dermatology and Therapy, 2023, 13(3): 673-688.
[11] HOU YF, TIAN CH, LIU HL, et al.Study on Applicability of ICH Guideline M1 Mapping Practice of National Adverse Drug Reaction Terminology[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(6): 333-337.
[12] NIKOLAOU VA, APALLA Z, CARRERA C, et al.Clinical Associations and Classification of Immune Checkpoint Inhibitor-Induced Cutaneous Toxicities: a Multicentre Study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients[J]. British Journal of Dermatology, 2022, 187(6): 962-969.
[13] KODALI N, BLANCHARD I, KUNAMNENI S, et al.Current Management of Generalized Pustular Psoriasis[J]. Experimental Dermatology, 2023, 32(8): 1204-1218.
[14] GISONDI P, BELLINATO F, GIROLOMONI G.Clinical Characteristics of Patients with Pustular Psoriasis: a Single-Center Retrospective Observational Study[J]. Vaccines, 2022, 10(8): 1171.
[15] MD KELLY AR, MD DEETI JP, MD ERICA BL, et al.Generalized Pustular Psoriasis: a Review of the Pathophysiology, Clinical Mani-festations, Diagnosis, and Treatment[J]. Cutis, 2022, 110(Suppl2): 19-25.
[16] PARASRAMANI SG, KAR BR, TAHILIANI S, et al.Management of Pustular Psoriasis; the Way Ahead[J]. Indian Journal of Dermatology, 2024, 69(3): 241-248.
[17] THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al.NCCN Guidelines^® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024[J]. Journal of the National Comprehensive Cancer Network, 2024, 22(9): 582-592.
[18] KRUEGER J, PUIG L, THAÇI D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis[J]. American Journal of Clinical Dermatology, 2022, 23(S1): 51-64.
[19] RODRÍGUEZ-FERNÁNDEZ K, MANGAS-SANJUÁN V, MERINO-SANJUÁN M, et al. Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis[J]. Pharmaceutics, 2022, 14(3): 654.